Enzalutamide versus Abiraterone Acetate as first-line treatment of castration resistant metastatic prostate cancer in geriatric (>= 75) patients


Alkan A., Guc Z. G., Gurbuz M., ozgun G., Degirmencioglu S., Dogan M., ...Daha Fazla

JOURNAL OF MENS HEALTH, cilt.17, sa.4, ss.128-134, 2021 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 17 Sayı: 4
  • Basım Tarihi: 2021
  • Doi Numarası: 10.31083/jomh.2021.041
  • Dergi Adı: JOURNAL OF MENS HEALTH
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.128-134
  • Anahtar Kelimeler: Metastatic castration-resistant prostate cancer, Enzalutamide, Abiraterone Acetate, Elderly, CHEMOTHERAPY, DOCETAXEL, SURVIVAL, OUTCOMES, SAFETY, MEN
  • Ankara Üniversitesi Adresli: Evet

Özet

Introduction: The efficacy and tolerability of Enzalutamide and Abiraterone Acetate have been reported in elderly patients with metastatic castration resistant prostate cancer (mCRPC). However, there is no randomized study directly comparing antitumor effects between these 2 agents in geriatric patients. We aimed to evaluate the efficacy of Enzalutamide (ENZA) and Abiraterone Acetate (AA) as a first-line treatment of mCRPC in elderly patients.